Saturday, September 11, 2010
"Concise industry news from the US pharmaceutical industry..."
Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Platinum Sponsors
Nanopoint, Inc.
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
is a privately-held biotechnology company that develops and markets unique cellular imaging systems for the life sciences market.
Read More
Gold Sponsors
Waters Corp.
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
For 50 years, Waters has developed innovative analytical science solutions to support customer discoveries, operations, performance, and regulatory compliance.
Read More
Silver Sponsors
Blog
Where our team of guest writers discuss what they think about the current NGP US Issues.
Peter Duncan
Director of Business Development
Director of Business Development
Can digital pathology save drug development?
Peter Duncan of Definiens discusses the potential of digital pathology.07 Jul 2010
Focus Area: Lead Features
Lead Features
Towards a greener future
GSK’s Mark Rhodes examines the level of environmental awareness in the pharmaceutical industry.
No Comments
Lifespans and livelihoods
In this address given to Town Hall Los Angeles in January, CEO of Eli Lilly and Company John Lechleiter.
No Comments
Curing the world's ills?
With emerging markets poised to contribute more than 50 percent of the pharmaceutical industry’s growth in the next year, most of the big players – and many of the smaller ones – now have a presence there. Marie Shields takes a look at what this means for the future of the industry.
No Comments
When the going gets tough
Joe Miletich tells NGP why it’s more important than ever for pharmaceutical R&D to pursue the highest levels of innovation.
No Comments
Source: www.ngpharma.com© 2010 GDS Publishing Ltd. All rights reserved.